Early studies employing CD30 Mabs to ameliorate HL did not reveal effective anti-tumor activity, possibly due to the inhibition of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis in heavily pretreated and immunosuppressed patients with HL [47]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.